The India pneumococcal vaccine market size reached USD 0.90 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1.30 Billion by 2033, exhibiting a growth rate (CAGR) of 3.80% during 2025-2033. The market is witnessing significant growth due to increasing awareness of vaccine-preventable diseases, rising healthcare access, and government immunization programs. Additionally, the market is driven by an enhanced focus on preventing pneumococcal infections, particularly in children and elderly populations, with an expanding range of vaccine options available.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 0.90 Billion |
Market Forecast in 2033 | USD 1.30 Billion |
Market Growth Rate 2025-2033 | 3.80% |
Government-Led Vaccination Programs
India’s pneumococcal vaccine market is expanding due to strong government intervention in immunization programs. Government-backed procurement and distribution have improved accessibility, reducing pneumonia-related mortality and morbidity. With continuous policy reinforcements, coverage is expected to increase further, particularly in rural areas where child mortality remains a concern. Additionally, partnerships between government agencies and vaccine manufacturers ensure stable supply chains, making vaccines more affordable. The expansion of routine immunization campaigns and increased healthcare funding for disease prevention are reinforcing market growth. For instance, in February 2024, the Government of Jharkhand announced that between November 2024 and February 2025, it administered 1.99 million pneumococcal conjugate vaccine doses under the SAANS campaign. This initiative aimed to reduce childhood pneumonia deaths by expanding vaccination coverage among children under five. Furthermore, future policies may focus on broader adult immunization, targeting high-risk groups like the elderly and individuals with chronic conditions. As India strengthens its public healthcare infrastructure, the pneumococcal vaccine market is poised to benefit from sustained government support, improving long-term disease control and prevention efforts nationwide.
Growing Indigenous Manufacturing and Cost Efficiency
India’s pneumococcal vaccine market has witnessed a shift toward domestic production, reducing reliance on costly imports. The introduction of locally produced PCVs has enhanced accessibility, particularly in low-income regions where cost remains a barrier. Domestic manufacturing also enables large-scale production, ensuring a consistent supply to meet rising demand. Moreover, India’s vaccine exports are also increasing, with these affordable alternatives gaining traction in global immunization programs. Additionally, continued investment in research and development (R&D) will enhance vaccine efficacy and adaptability, addressing regional serotype variations. For instance, in July 2024, Biological E. Limited announced the progression of Phase IV clinical trials for its 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX-14). The trials, approved in October 2024, aim to evaluate the immunogenicity and safety of the vaccine in healthy children aged 5 to under 18 and adults aged 18 and above. As domestic manufacturers scale up production, India’s pneumococcal vaccine market is likely to grow steadily, with affordability and availability driving higher immunization rates across diverse population segments.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2025-2033. Our report has categorized the market based on vaccine type, product type, distribution channel, and end user.
Vaccine Type Insights:
The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
Product Type Insights:
A detailed breakup and analysis of the market based on the product type have also been provided in the report. This includes prevnar 13, synflorix, and pneumovax 23.
Distribution Channel Insights:
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes distribution partner companies, non-governmental organizations (NGO), and government authorities.
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes pediatrics and adults.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North India, South India, East India, and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Vaccine Types Covered | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
Product Types Covered | Prevnar 13, Synflorix, Pneumovax 23 |
Distribution Channels Covered | Distribution Partner Companies, Non-Governmental Organizations (NGO), Government Authorities |
End Users Covered | Pediatrics, Adults |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: